BFRI
Biofrontera Inc.
$1.14
-0.02 (-1.72%)
At close · Jul 8
Market Cap
$14.60M
Shares
12,803,344
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.14
Open$1.16
Day$1.05–1.17
52W$0.56–1.21
Avg vol 30d285K
Short int28K · 0.2% float · 1.0d
Short vol57%
Last earningsMay 14, 2026
DataOct 2021–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+16%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+23%
trailing
6-month return
+42%
trailing
YTD return
+100%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-14% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.22% of float · ▼ -50.2% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
25
low risk · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+68%
Y/Y
Free cash flow
$-13.4M
Balance sheet
$6.4M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-14% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.22% of float · ▼ -50.2% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 90%
52-wk high $1
vs 200-day avg +23%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$3.6M | Q1 2026 | — |
| Adjusted EBITDA margin non-GAAP | -35.3% | first quarter of 2026 | — |
| Ameluz units sold growth | 16% | first quarter of 2026 | — |
| Cash used in operations | $70K | Q1 2026 | — |
| Operating cash balance | $6.3M | as of March 31, 2026 | — |
| Gross margin | 82.4% | 4Q25 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BFRI
this stock
Biofrontera Inc.
|
$14.60M | +100.0% | +19.0% | — | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.92B | +6.5% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.23B | +4.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.05B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BFRI | +20.5% | +22.6% | +42.0% | +20.5% | +100.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +20.7% | +21.7% | +34.5% | +20.7% | +90.7% |